Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNP 105

Drug Profile

BNP 105

Alternative Names: BNP-105

Latest Information Update: 27 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMS
  • Class Antiulcers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Aphthous stomatitis

Most Recent Events

  • 22 Jan 2024 Phase-I clinical trials in Aphthous stomatitis (In volunteers, In adolescents, In adults, In the elderly) in Brazil (PO) (NCT05772338)
  • 16 Mar 2023 EMS plans to initiate a clinical trial to evaluate the efficacy and safety of BNP 105 in aphthous stomatitis in female participants (Recurrent, In volunteers, In adolescent, In adults, In the elderly) in Brazil (PO, Suspension) in October 2023 (NCT05772338)
  • 16 Mar 2023 Preclinical trials in Aphthous stomatitis in Brazil (PO) (NCT05772338)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top